ACELYRIN, Inc.

ACELYRIN, Inc. (SLRN) priced its initial public offering on May 5, 2023 at $18.00 per share, within its $16.00–$18.00 range, raising $540M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.67B. Cooley advised the company and Davis Polk advised the underwriters.

ACELYRIN, Inc. is a late-stage clinical biopharmaceutical company that identifies, acquires and develops medicines for diseases tied to excess activation of the immune system. It acquired its portfolio of product candidates with the aim of developing and commercializing new therapies.

Status

IPO

Ticker

SLRN

Exchange

Nasdaq Global Select

Priced

May 5, 2023

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$540M

Market cap at IPO price

$1.67B

First filed

Apr 13, 2023

Company counsel

Cooley

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.